BIO-LOSARTAN TABLET
Krajina: Kanada
Jazyk: angličtina
Zdroj: Health Canada
Súhrn charakteristických
(SPC)
23-09-2015
Niektoré dokumenty týkajúce sa tohto produktu nie sú momentálne k dispozícii, môžete poslať požiadavku na náš zákaznícky servis a my vás upozorníme hneď, ako ich dokážeme získať.
Poslať žiadosť.
Poslať žiadosť.
Aktívna zložka:
LOSARTAN POTASSIUM
Dostupné z:
BIOMED PHARMA
ATC kód:
C09CA01
INN (Medzinárodný Name):
LOSARTAN
Dávkovanie:
100MG
Forma lieku:
TABLET
Zloženie:
LOSARTAN POTASSIUM 100MG
Spôsob podávania:
ORAL
Počet v balení:
100
Typ predpisu:
Prescription
Terapeutické oblasti:
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Prehľad produktov:
Active ingredient group (AIG) number: 0127971002; AHFS:
Stav Autorizácia:
CANCELLED POST MARKET
Dátum Autorizácia:
2022-07-19
Súhrn charakteristických
_Bio-LOSARTAN _
_Page 1 of 36_
PRODUCT MONOGRAPH
PR BIO-LOSARTAN
Losartan Potassium Tablets
25, 50 and 100 mg
(House Standard)
Angiotensin II Receptor Antagonist
BIOMED PHARMA DATE OF PREPARATION:
100-5950, Ch. de la Côte de Liesse September 14, 2015
Mont-Royal
Qc, H4T 1E2
Control # 186979
_Bio-LOSARTAN _
_Page 2 of 36_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION................................................................
3
SUMMARY PRODUCT INFORMATION
....................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
3
CONTRAINDICATIONS
...............................................................................................................
3
WARNINGS AND PRECAUTIONS
..............................................................................................
4
ADVERSE REACTIONS
................................................................................................................
7
DRUG INTERACTIONS
................................................................................................................
9
DOSAGE AND ADMINISTRATION
..........................................................................................
11
OVERDOSAGE
............................................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
........................................................................
13
STORAGE AND STABILITY
......................................................................................................
16
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................... 16
PART II: SCIENTIFIC INFORMATION
.....................................................................................
17
PHARMACEUTICAL INFORMATION
......................................................................................
17
CLINICAL
Prečítajte si celý dokument
